Clinical trial: Combining durvalumab with novel agents increases pathological responses in resectable NSCLC
Phase 2 results from the NeoCOAST-2 study have demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete response rates among the tested regimens.
